STAT1 and breast carcinoma: Most efforts to circumvent this issue involve downregulating STAT1 expression via concomitant administration of STAT1 inhibitors, such as the use of Epigallocatechin 3-gallate (EGCG) against endocrine-resistant breast cancer reported by Huang et al. [34].